Cost-Effectiveness Analyses of Adolescent- and Young-Adult-Focused HIV Interventions Incorporating HIV Transmission: a Scoping Review of Modeling Methods and Proposed Guidance

Wanyi Chen, Simeng Li, Carol Mita, Sarah E. Rutstein, Audrey Pettifor, John Giardina, Kenneth Freedberg, Kimberly A. Powers, Andrea Ciaranello and Anne M. Neilan ()
Additional contact information
Wanyi Chen: Massachusetts General Hospital
Simeng Li: Massachusetts General Hospital
Carol Mita: Harvard Medical School
Sarah E. Rutstein: University of North Carolina
Audrey Pettifor: University of North Carolina
John Giardina: Massachusetts General Hospital
Kenneth Freedberg: Massachusetts General Hospital
Kimberly A. Powers: University of North Carolina
Andrea Ciaranello: Massachusetts General Hospital
Anne M. Neilan: Massachusetts General Hospital

PharmacoEconomics - Open, 2025, vol. 9, issue 5, No 4, 739-755

Abstract: Abstract Background Adolescents and young adults (AYA) are disproportionately affected by human immunodeficiency virus (HIV) globally, with high-burden population subgroups differing across regions. Cost-effectiveness modeling analyses of AYA-focused HIV interventions have provided vital information to policy makers by projecting long-term health and economic impacts of interventions’ effects on reduced HIV transmission. To provide a broad overview of available modeling approaches and identify gaps in methods reporting, we evaluated modeling methodologies used in AYA-focused cost-effectiveness analyses incorporating HIV transmission. Methods We searched PubMed, Embase, and Web of Science for peer-reviewed articles that were published January 2006 to August 2023 and described models that considered HIV transmission in estimating cost-effectiveness of AYA-focused HIV prevention interventions. We extracted selected study characteristics, transmission model properties, and methods to estimate long-term health and economic outcomes. We assessed study quality using published guidelines. Results Among 42 studies, 38% included individuals assigned male or female sex at birth, 19% included females only, and 43% included males only; 24% focused on AYA only; 88% were set in Africa; and 7% were restricted to certain population subgroups. The most common population subgroups examined were women who have transactional sex (24%) and men who have sex with men (17%). Most (88%) studied primary prevention interventions for people at risk of HIV; 29% examined secondary prevention interventions including treatment and testing. Most (98%) assessed incremental cost-effectiveness ratios (ICERs) were defined as incremental cost per incremental life year (either quality-adjusted or disability-adjusted), or cost per infection averted, or both. Of 24 different transmission models identified with distinct structures, 59% were dynamic. Of 20 studies that translated averted infections into long-term health benefit, 55% used their transmission models directly through assigning health utilities to modeled states. A total of 30 studies converted averted infections into long-term cost savings, among which, 73% used their transmission models directly by assigning costs to modeled states. Fewer than half captured age-specific sexual and care-engagement behaviors. Important gaps in quality included incomplete reporting of model validation and calibration results. Conclusions We identified heterogeneous modeling approaches in cost-effectiveness analyses of AYA-focused HIV interventions incorporating transmission. Reporting of key elements could be improved. We propose additional criteria that could clarify choices around modeling approaches and strengthen the reporting of model validation and calibration results.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-025-00583-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:9:y:2025:i:5:d:10.1007_s41669-025-00583-1

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-025-00583-1

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().